Insmed, Inc. (NASDAQ:INSM) Short Interest Update

Insmed, Inc. (NASDAQ:INSM) saw a large growth in short interest in December. As of December 31st, there was short interest totaling 11,015,687 shares, a growth of 23.4% from the December 15th total of 8,927,430 shares. Based on an average daily volume of 4,718,921 shares, the short-interest ratio is currently 2.3 days. Approximately 5.3% of the company’s stock are short sold. Approximately 5.3% of the company’s stock are short sold. Based on an average daily volume of 4,718,921 shares, the short-interest ratio is currently 2.3 days.

Insider Transactions at Insmed

In related news, insider Michael Alexander Smith sold 1,053 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $174.17, for a total value of $183,401.01. Following the completion of the sale, the insider owned 57,037 shares of the company’s stock, valued at approximately $9,934,134.29. The trade was a 1.81% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO William Lewis sold 19,215 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the transaction, the chief executive officer directly owned 306,891 shares in the company, valued at approximately $51,864,579. The trade was a 5.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 286,100 shares of company stock valued at $52,595,894 over the last 90 days. Company insiders own 3.00% of the company’s stock.

Institutional Trading of Insmed

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in shares of Insmed by 13.0% in the 3rd quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock valued at $2,870,957,000 after purchasing an additional 2,291,328 shares in the last quarter. Norges Bank bought a new position in Insmed during the 2nd quarter valued at about $194,728,000. Artisan Partners Limited Partnership boosted its position in Insmed by 49.0% in the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after buying an additional 1,623,342 shares in the last quarter. Orbis Allan Gray Ltd acquired a new position in Insmed in the second quarter valued at about $153,389,000. Finally, Darwin Global Management Ltd. grew its stake in Insmed by 5.8% during the third quarter. Darwin Global Management Ltd. now owns 20,457,445 shares of the biopharmaceutical company’s stock worth $2,897,797,000 after buying an additional 1,112,824 shares during the last quarter.

Insmed Price Performance

Shares of Insmed stock opened at $163.51 on Wednesday. The firm has a market cap of $34.87 billion, a P/E ratio of -26.42 and a beta of 1.08. The firm’s 50-day simple moving average is $186.51 and its 200-day simple moving average is $155.65. Insmed has a twelve month low of $60.40 and a twelve month high of $212.75. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The business had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The business’s revenue for the quarter was up 52.4% on a year-over-year basis. During the same period last year, the company earned ($1.27) EPS. As a group, research analysts expect that Insmed will post -4.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Evercore ISI reaffirmed an “outperform” rating and set a $180.00 price objective on shares of Insmed in a report on Wednesday, October 1st. Rothschild & Co Redburn began coverage on shares of Insmed in a research report on Thursday, December 4th. They set a “buy” rating and a $263.00 target price for the company. Redburn Partners set a $263.00 price target on Insmed in a research report on Thursday, December 4th. TD Cowen dropped their price objective on Insmed from $269.00 to $241.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Finally, HC Wainwright decreased their target price on Insmed from $240.00 to $230.00 and set a “buy” rating for the company in a research note on Thursday, December 18th. Two analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $205.77.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.